Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Assessing PFS and alternative endpoints for advanced cancer clinical trials

Jurjen Versluis • 22 Apr 2024
EBMT 2024
General

Jurjen Versluis, MD, PhD, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses progression-free survival (PFS) as an endpoint in advanced cancer clinical trials and other endpoints that may be suitable alternatives. Dr Verluis emphasizes the importance of long-term follow-up to assess overall survival (OS) benefits, as well as the validation of alternative endpoints such as measurable residual disease (MRD). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jurjen Versluis

1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024

Related Videos

4:09
Veno-occlusive disease as a post-transplant complication of HSCT
Mohamad Mohty • 17 Apr 2024
1:56
Addressing access inequality in CAR-T therapies
Francesca Del Bufalo • 15 Apr 2024
1:34
The future role of AI models in hematology and the need for high-quality data sets
Thomas Coats • 29 Apr 2024
6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals